

Rezurock (belumosudil)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Rezurock (belumosudil) 200 mg	1 tablet per day*

***Increase of dosage of Rezurock to 200 mg twice daily may be approved when co-administered with proton pump inhibitors or strong CYP3A inducers** (including, but not limited to: apalutamide, carbamazepine, enzalutamide, fosphenytoin, lumacaftor/lumacaftor-ivacaftor, mitotane, phenobarbital, phenytoin, primidone, rifampin).

APPROVAL CRITERIA

Requests for Rezurock (belumosudil) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of relapsed or refractory chronic Graft versus Host Disease (cGVHD); **AND**
- III. Individual has failed at least two prior lines of systemic therapy.

Requests for Rezurock may not be approved for the following:

- I. Individual has severe hepatotoxicity (Grade 4 AST or ALT (more than 20x ULN) or Grade ≥ 3 bilirubin (more than 3x ULN)).

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.